Welcome to our dedicated page for Silo Pharma SEC filings (Ticker: SILO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking a developmental-stage biotech like Silo Pharma means wading through pages of clinical trial costs, licensing terms, and patent language. Whether you鈥檙e searching for 鈥淪ilo Pharma insider trading Form 4 transactions鈥� or trying to locate the exact burn-rate hidden in a 300-page annual report, the company鈥檚 filings can feel impenetrable.
Stock Titan鈥檚 AI reads every 10-K, 10-Q, 8-K, and Form 4 the moment it hits EDGAR and translates them into plain English. Need a quick take on the latest 鈥淪ilo Pharma quarterly earnings report 10-Q filing鈥�? Our AI-powered summaries highlight R&D spend, cash runway, and key milestones in seconds. Wondering about 鈥淪ilo Pharma executive stock transactions Form 4鈥� before the next financing round? AG真人官方-time alerts surface each trade, complete with context. From 鈥淪ilo Pharma proxy statement executive compensation鈥� tables to 鈥淪ilo Pharma 8-K material events explained鈥�, complex biotech disclosures are now searchable, sortable, and understandable.
Dig deeper into what matters for a psychedelic-focused pipeline: see how university collaboration payments flow quarter over quarter, compare intellectual-property additions across years, and spot any dilution risks flagged in S-3 registrations. Investors use these insights to monitor trial progression (SPC-15, SP-26), assess non-dilutive funding potential, and evaluate management alignment through 鈥淪ilo Pharma Form 4 insider transactions real-time鈥�. Understanding Silo Pharma SEC documents with AI isn鈥檛 a luxury鈥攊t鈥檚 how professionals make informed calls on this evolving CNS therapeutics story.
Silo Pharma, Inc. (SILO) reported consolidated interim results showing a net loss of $2,235,730 for the six months ended June 30, 2025, compared with a $1,733,446 loss in the same period of 2024, reflecting larger operating losses. Research and development and professional fees were significant components of operating expenses, with R&D of $1,311,209 and professional fees of $573,416 for the six months in 2025. Net cash used in operating activities reflected the loss offset by non-cash items (amortization $5,565, stock-based compensation $17,445, net realized gain $3,911) and working capital changes.
The company reported net cash provided by investing activities of $1,259,483 (principally proceeds from sale of short-term investments) and net cash provided by financing activities of $2,093,958 (including $1,593,897 from sale of common stock/pre-funded warrants and $500,061 from exercises), producing a net increase in cash of $427,873 for the period.
Silo Pharma is a developmental-stage biopharmaceutical and cryptocurrency treasury company advancing therapies for PTSD, fibromyalgia, Alzheimer鈥檚 and multiple sclerosis. The company reported cash and cash equivalents of $4.33 million and short-term investments of $1.93 million, giving total assets of $6.65 million and working capital of $5.32 million. Management states available cash and liquid investments are sufficient to meet obligations for at least twelve months.
Operating results show a six-month net loss of $2.24 million versus $1.73 million a year earlier, driven by higher research and development expense of $1.31 million (six months) and total operating expenses of $2.38 million. License fee revenue remains nominal ($36,051 six months) with one licensee accounting for 100% of that revenue. Financing activity increased shares outstanding from 4.48 million to 8.65 million and generated net proceeds of $1.59 million from a May 2025 offering. Outstanding warrants totaled 8,295,072, and intangible assets include a Columbia license revised to $235,000.
This Schedule 13G/A reports that Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital LLC collectively may beneficially own 838,081 shares of Silo Pharma common stock, representing approximately 9.99% of the outstanding common shares. That reported stake primarily reflects 833,334 shares issuable upon exercise of one warrant and 4,747 shares issuable upon exercise of a second warrant.
The filing shows the Reporting Persons have no sole voting or dispositive power and instead hold shared voting and dispositive power over the 838,081 shares. Several additional warrants are subject to blocker provisions that prevent exercise to the extent that conversion would push ownership above certain thresholds; excluding those blocked amounts, the Reporting Persons could be deemed to beneficially own 2,392,524 shares. The filing includes a certification that the securities are not held to change or influence control of the issuer.
Silo Pharma (SILO) filed an 8-K to disclose a strategic shift toward digital assets. On 4 Aug 2025 the Board formed a Cryptocurrency Advisory Board of up to three members to guide a newly adopted cryptocurrency treasury strategy. The Board simultaneously appointed Corwin Yu as the first advisor and executed an agreement granting him 45,000 stock options at an exercise price of $0.7757. The options vest in 12 equal monthly tranches under the Amended & Restated 2020 Omnibus Equity Incentive Plan. A press release announcing the initiative was issued on 5 Aug 2025 and filed as Exhibit 99.1.
No financial results, guidance, or capital-raising transactions were reported. The filing is limited to governance changes and does not alter prior disclosures.
FAQ
What is the current stock price of Silo Pharma (SILO)?
What is the market cap of Silo Pharma (SILO)?
